Herceptin, Trastuzumab Newswire (Page 7)

Herceptin, Trastuzumab Newswire (Page 7)

Comprehensive Real-Time News Feed for Herceptin, Trastuzumab (generic). (Page 7)

Results 121 - 140 of 963 in Herceptin, Trastuzumab (generic)

  1. Triple-negative breast cancer target is foundRead the original story w/Photo

    May 13, 2016 | PhysOrg Weblog

    UC Berkeley researchers have found a long-elusive Achilles' heel within "triple-negative" breast tumors, a common type of breast cancer that is difficult to treat. The scientists then used a drug-like molecule to successfully target this vulnerability, killing cancer cells in the lab and shrinking tumors in mice.

    Comment?

  2. Abstract P4-14-06: Neoadjuvant chemotherapy with docetaxel,...Read the original story

    May 12, 2016 | CiteULike

    Abstract P4-14-06: Neoadjuvant chemotherapy with docetaxel, carboplatin and weekly trastuzumab is active in HER2-positive early breast cancer: Results after a median follow-up of over 4 years Cancer Research , Vol. 76, No.

    Comment?

  3. Up to 55% price cut for cancer drugs, 53 othersRead the original story w/Photo

    May 11, 2016 | The Times of India

    Prices of these medicines have been fixed on priority because these are commonly used and are new to the list. Prices of these medicines have been fixed on priority because these are commonly used and are new to the list.

    Comment?

  4. .com | Unaffordable healthcare is fatal for the poor - MotsoalediRead the original story w/Photo

    May 10, 2016 | News24

    Ranting on social media about your frustrations is wrong, but people should try and understand where this white frustration is coming from, writes Robin Mun-Gavin . Cape Town If no drastic action is taken against unaffordable cancer and TB drugs, the country will be counting body bags like it was at war, Health Minister Aaron Motsoaledi said on Tuesday.

    Comment?

  5. Biosimilars in India News: Recent Guidelines from India's CDSCO ...Read the original story w/Photo

    May 9, 2016 | JD Supra

    A recent court ruling and a new publication on guidelines for biosimilars in India may offer further guidance on what biosimilar and biologic stakeholders can expect from Indian regulatory authorities. In late March, India's Central Drugs Standard Control Organization published Proposed Revised Guidelines on Similar Biologics , offering guidance on the regulatory requirements for biosimilars in India.

    Comment?

  6. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in...Read the original story

    May 5, 2016 | CiteULike

    Trastuzumab emtansine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. We characterized the incidence of central nervous system metastases after treatment with trastuzumab emtansine versus capecitabine-lapatinib , and treatment efficacy among patients with pre-existing CNS metastases in the phase III EMILIA study.

    Comment?

  7. Amgen (AMGN) Robert A. Bradway on Q1 2016 Results - Earnings Call TranscriptRead the original story w/Photo

    Apr 28, 2016 | Seeking Alpha

    My name is Jade, and I'll be your conference facilitator today for Amgen's first quarter 2016 financial results conference call. All lines have been placed on mute to prevent any background noise.

    Comment?

  8. Delhi High Court order on copies of Roche's cancer drug draws flakRead the original story w/Photo

    Apr 27, 2016 | The Times of India

    The April 25 order, which raised questions on the processes followed by the Indian drug controller in approving such drugs, could also affect the availability and affordability of an expensive cancer treatment, said an industry executive. MUMBAI: Makers of biosimilar drugs are unhappy with a Delhi High Court ruling that imposed certain conditions on Biocon and Mylan to sell copies of Roche's blockbuster biotech-based breast cancer drug, trastuzumab.

    Comment?

  9. High Court order not to affect product portfolio, says BioconRead the original story w/Photo

    Apr 26, 2016 | DNA India

    Delhi High Court had prevented Biocon from calling its breast cancer medicine Trastuzumab as a biosimilar of Roche's Herceptin. Delhi High Court had prevented Biocon from calling its breast cancer medicine Trastuzumab as a biosimilar of Roche's Herceptin.

    Comment?

  10. HC nod to desi cos' version of cancer drug, but with curbsRead the original story w/Photo

    Apr 25, 2016 | The Times of India

    The Delhi high court on Monday allowed the sale and manufacture of breast cancer drug trastuzumab by Biocon and Reliance Life Sciences, with certain restrictions.

    Comment?

  11. Study finds explanation for some treatment-resistant breast cancersRead the original story w/Photo

    Apr 21, 2016 | PhysOrg Weblog

    From left are: Carlos L. Arteaga, M.D., director of the VICC Breast Cancer Program and the Center for Cancer Targeted Therapies, Justin Balko, Pharm.D., Ph.D., and Luis Schwarz, M.D. Credit: Vanderbilt University Medical Center A targeted therapy for triple-negative breast cancer , the most aggressive form of breast cancer, has shown potential promise in a recently published study. TNBC is the only type of breast cancer for which there are no currently approved targeted therapies.

    Comment?

  12. Breast cancer drug Herceptin increases heart damage risk, study saysRead the original story w/Photo

    Apr 20, 2016 | UPI

    Although doctors already monitor older breast cancer patients for heart damage if their treatment includes the drug trastuzumab, researchers suggest all patients on the drug should be monitored based on the results of a recent study. Researchers in Canada report in a study, published in the Journal of Clinical Oncology , that the drug significantly increased the risk for major cardiac events among all patients, regardless of age.

    Comment?

  13. Puma Biotechnology's Neratinib Featured in Poster Presentations at the AACR Annual Meeting 2016Read the original story

    Apr 20, 2016 | Freshnews

    Puma Biotechnology, Inc. , a biopharmaceutical company, announced that its drug candidate neratinib was highlighted in three poster presentations at the American Association for Cancer Research Annual Meeting 2016. The AACR Annual Meeting was held at the Ernest N. Morial Convention Center in New Orleans from April 16 to April 20. Abstract Number 298: Amplification of mutant ERBB2 drives resistance to the irreversible kinase inhibitor neratinib in ERBB2-mutated breast cancer patients.

    Comment?

  14. Herceptin drugs for breast cancer linked with increased risk of congestive heart failureRead the original story w/Photo

    Apr 20, 2016 | Medical News

    Breast cancer patients undergoing treatment with trastuzumab-containing regimens should be monitored for heart damage regardless of age. This is among the findings of a new study from the Peter Munk Cardiac Centre, the Institute for Clinical Evaluative Sciences and the Ted Rogers Centre for Heart Research, University Health Network .

    Comment?

  15. Breast cancer patients receiving Herceptin treatment should be monitored for heart damage at any ageRead the original story w/Photo

    Apr 20, 2016 | Medical News Today

    Breast cancer patients undergoing treatment with trastuzumab-containing regimens should be monitored for heart damage regardless of age, according to a new multi-centre study in Ontario. Breast cancer patients undergoing treatment with trastuzumab-containing regimens should be monitored for heart damage regardless of age.

    Comment?

  16. Breast Cancer Patients Undergoing Herceptin Treatment Should Be...Read the original story

    Apr 19, 2016 | Newswise

    TORONTO, APRIL 19, 2016 - Breast cancer patients undergoing treatment with trastuzumab-containing regimens should be monitored for heart damage regardless of age. This is among the findings of a new study from the Peter Munk Cardiac Centre, the Institute for Clinical Evaluative Sciences and the Ted Rogers Centre for Heart Research, University Health Network .

    Comment?

  17. New drug combination before surgery may improve outcomes in breast cancer patientsRead the original story w/Photo

    Apr 19, 2016 | Medical News

    Results from the I-SPY 2 trial show that giving patients with HER2-positive invasive breast cancer a combination of the drugs trastuzumab emtansine and pertuzumab before surgery was more beneficial than the combination of paclitaxel plus trastuzumab. Previous studies have shown that a combination of T-DM1 and pertuzumab is safe and effective against advanced, metastatic HER2-positive breast cancer, but in the new results, investigators tested whether the combination would also be effective if given earlier in the course of treatment.

    Comment?

  18. Evidence show new drug combination may improve outcomes for women with advanced breast cancerRead the original story w/Photo

    Apr 18, 2016 | PhysOrg Weblog

    Results from the I-SPY 2 trial show that giving patients with HER2-positive invasive breast cancer a combination of the drugs trastuzumab emtansine and pertuzumab before surgery was more beneficial than the combination of paclitaxel plus trastuzumab. Previous studies have shown that a combination of T-DM1 and pertuzumab is safe and effective against advanced, metastatic HER2-positive breast cancer, but in the new results, investigators tested whether the combination would also be effective if given earlier in the course of treatment.

    Comment?

  19. Many older black women miss out on targeted breast cancer drugRead the original story w/Photo

    Apr 18, 2016 | Fox News

    Older black women with human epidermal growth factor receptor 2 -positive breast cancer are less likely than their white peers to receive targeted therapy with trastuzumab , a U.S. study suggests. When researchers examined data from Medicare, the U.S. health program for people over age 65, they found just 40 percent of black women with HER2-positive tumors received trastuzumab, compared with 50 percent of white women.

    Comment?

  20. Penn Medicine presents evidence showing new drug combination may...Read the original story w/Photo

    Apr 17, 2016 | EurekAlert!

    Results from the I-SPY 2 trial show that giving patients with HER2-positive invasive breast cancer a combination of the drugs trastuzumab emtansine and pertuzumab before surgery was more beneficial than the combination of paclitaxel plus trastuzumab. Previous studies have shown that a combination of T-DM1 and pertuzumab is safe and effective against advanced, metastatic HER2-positive breast cancer, but in the new results, investigators tested whether the combination would also be effective if given earlier in the course of treatment.

    Comment?